% 0期刊文章% Joohi Jimenez-Shahed %一个苏珊Bressman %米歇尔Burack %伊Farace %一个詹姆斯•杰•麦克伦尼%詹姆斯·柯克% Jason Schwalb瑞秋Saunders-Pullman % %一个梅雷迪斯•斯宾德勒施Ludy % %埃琳娜·莫罗%米歇尔纽约% T RAD-PD:注册DBS在促进帕金森病(P4.064) % D J神经病学2018% % P P4.064 % V 90% N 15补充% X目的:描述脑深部刺激(DBS)注册中心提案改善的目的DBS疗法和帕金森病(PD)患者的治疗结果。首页背景:尽管大量证据支持DBS在继续最好的医疗管理在麻烦的运动并发症出现在PD,变化的结果不是很好理解,最佳实践是不明确的,和潜在的长期的健康经济数据和处理技术比较缺乏。随机试验是不切实际的探讨这些问题。设计/方法:调查潜在的临床基地调查临床数据通常被俘。RAD-PD设计作为质量改进的努力。一个大型和异构PD组进行DBS将前瞻性,全面使用标准评估电池和图像分析的特点。Clinician-measured和病人报告结果和成像将从超过1000个参与者聚集在40临床基地在5年的DBS疗法。结果:在25网站回应,96%完成一个MDS-UPDRS第三部分,70 - 77%完成我MDS-UPDRS部分,第二和第四,91%完成Hoehn Yahr登台,85%完成MoCA手术前。绝大多数不系统地评估非症状或冲动控制障碍,只有68%捕获PDQ-39。没有受访者评估手术风险和病人满意度。设计了一组全面的数据元素是系统地捕获和RAD-PD基准测试进行分析。 Dashboarding to participating sites will enable them to consider implementing changes in therapeutic strategies to improve the quality of DBS care and outcomes for PD patients.Conclusions: RAD-PD is needed to prospectively capture standard and comprehensive assessments in a large PD cohort undergoing DBS, with the primary goal of improving DBS therapy and outcomes. Results will have broad applicability to a range of practice scenarios and patient characteristics and the infrastructure can be applied to other disease states.Study Supported by: Michael J Fox Foundation, Parkinson Study GroupDisclosure: Dr. Jimenez-Shahed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, St. Jude Medical, Medtronic. Dr. Jimenez-Shahed has received research support from Avid Radiopharmaceuticals, Acadia Pharmaceuticals, St. Jude Medical, Biotie, Michael J. Fox Foundation. Dr. Bressman has nothing to disclose. Dr. Burack has nothing to disclose. Dr. Farace has nothing to disclose. Dr. McInerney has nothing to disclose. Dr. Kirk has nothing to disclose. Dr Saunders-Pullman has nothing to disclose. Dr. Schwalb has nothing to disclose. Dr. Shih has nothing to disclose. Dr. Spindler has nothing to disclose. Dr. Moro has nothing to disclose. Dr. York has nothing to disclose. %U